Massive gap higher at the open, I was waiting for a dip, but it never came!
News: Shares of Alnylam Pharmaceuticals Inc. (ALNY) soared 31.1% to $98.35 in premarket trading on Wednesday, Sept. 20, after the Cambridge, Mass.-based company and Sanofi Genzyme unveiled positive topline results from a Phase 3 study of patisiran, which is being developed for patients with hereditary ATTR amyloidosis with polyneuropathy. -thestreet.com
Submitted September 20, 2017 at 10:01AM by StockJock-e http://ift.tt/2jKOpb5
No comments:
Post a Comment